Table 1. Clinical characteristics of NSCLC patients (n = 153).
| Characteristic | NSCLC patients | p-valueb | |||
|---|---|---|---|---|---|
| EGFR19DEL (n = 64) | EGFRp.L858R (n = 36) | EGFRMUT(+)a (n = 100) | EGFRWT (n = 53) | ||
| Age (years), mean (range) | 56.3 (37–76) | 61.1 (34–80) | 57.9 (34–80) | 59.0 (34–84) | 0.537 |
| Sex, n (%) | |||||
| M | 29 (45.3) | 17 (47.2) | 46 (46.0) | 26 (49.1) | |
| F | 35 (54.7) | 19 (52.8) | 54 (54.0) | 27 (50.9) | 0.424 |
| ECOG PS, n (%) | |||||
| 0 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| 1 | 64 (100.0) | 36 (100.0) | 100 (100.0) | 53 (100.0) | |
| 2 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | N/A |
| Complications, n (%) | |||||
| Y | 17 (26.6) | 9 (25.0) | 26 (26.0) | 18 (34.0) | |
| N | 47 (73.4) | 27 (75.0) | 74 (74.0) | 35 (66.0) | 0.198 |
| Smoker, n (%) | |||||
| Y | 22 (34.4) | 13 (36.1) | 35 (35.0) | 28 (52.8) | |
| N | 42 (65.6) | 23 (63.9) | 65 (65.0) | 25 (47.2) | 0.025* |
| FH of cancer, n (%) | |||||
| Y | 8 (12.5) | 5 (13.9) | 13 (13.0) | 10 (18.9) | |
| N | 56 (87.5) | 31 (86.1) | 87 (87.0) | 43 (81.1) | 0.231 |
| cStage, n (%) | |||||
| IIIA–B | 7 (10.9) | 3 (8.3) | 10 (10.0) | 9 (17.0) | |
| IV | 57 (89.1) | 33 (91.7) | 90 (90.0) | 44 (83.0) | 0.161 |
| Histology, n (%) | |||||
| ADC | 59 (92.2) | 34 (94.4) | 93 (93.0) | 51 (96.2) | |
| ADC+SCC | 5 (7.8) | 2 (5.6) | 7 (7.0) | 2 (3.8) | 0.340 |
* p < 0.05
a EGFR19DEL and EGFRp.L858R patients combined
bEGFRMUT(+) versus EGFRWT
Abbreviations: 19DEL, exon 19 deletion; ADC, adenocarcinoma; cStage, clinical stage; ECOG, Eastern Cooperative Oncology Group; F, female; FH, family history; M, male; MUT(+), mutation-positive; N, no; N/A, not applicable; PS, performance status; SCC, squamous cell carcinoma; WT, wild-type; Y, yes